scholarly journals In Vitro Study of the Metabolic Characteristics of Eight Isoquinoline Alkaloids from Natural Plants in Rat Gut Microbiota

Molecules ◽  
2017 ◽  
Vol 22 (6) ◽  
pp. 932 ◽  
Author(s):  
Chi-Yu He ◽  
Jie Fu ◽  
Jia-Wen Shou ◽  
Zhen-Xiong Zhao ◽  
Long Ren ◽  
...  
Planta Medica ◽  
2016 ◽  
Vol 81 (S 01) ◽  
pp. S1-S381
Author(s):  
EM Pferschy-Wenzig ◽  
K Koskinen ◽  
C Moissl-Eichinger ◽  
R Bauer

Chemosphere ◽  
2017 ◽  
Vol 168 ◽  
pp. 358-364 ◽  
Author(s):  
Naiyi Yin ◽  
Xiaolin Cai ◽  
Huili Du ◽  
Zhennan Zhang ◽  
Zejiao Li ◽  
...  

2021 ◽  
Author(s):  
Hitache Zeyneb ◽  
Hairun Pei ◽  
Xueli Cao ◽  
Yuxin Wang ◽  
Yumon Win ◽  
...  

2020 ◽  
Vol 2020 ◽  
pp. 1-11
Author(s):  
Youfa Qin ◽  
Yongkun Zhu ◽  
Xiaoyan Xue ◽  
Guanghui Zhou ◽  
Huibo Li ◽  
...  

Kurarinone is a major component found in the dried roots of Sophora flavescens Ait. that participates in vital pharmacological activities. Recombinant CYP450 supersomes and liver microsomes were used to study the metabolic profiles of kurarinone and its inhibitory actions against cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes. 100 μM of kurarinone strongly inhibited more than 90% of UGT1A1, UGT1A6, CYP1A2, and CYP2C9. CYP1A2 and CYP2D6 played important roles in catalyzing the biotransformation of kurarinone. Moreover, metabolism of kurarinone considerably differs among species, and metabolic characteristics were similar between monkey and human. Kurarinone demonstrated moderate permeability at values of pH 4.0 and 7.4. Our findings offer a clearer idea to understand the pharmacological and toxicological mechanisms of kurarinone.


2019 ◽  
Vol 6 ◽  
Author(s):  
Sophie Fehlbaum ◽  
Christophe Chassard ◽  
Clarissa Schwab ◽  
Maarja Voolaid ◽  
Candice Fourmestraux ◽  
...  

Author(s):  
Lynne Bell ◽  
Adrian Whyte ◽  
Cindy Duysburgh ◽  
Massimo Marzorati ◽  
Pieter Van den Abbeele ◽  
...  

Abstract Purpose Cereboost®, an American ginseng extract, has shown improved short-term memory and attention/alertness in healthy young and middle-aged individuals, potentially via modulation of the gut microbiome and upregulation of neurotransmitters such as acetylcholine. Here, we explored the effects of Cereboost® on cognition and mood in the first 6 h post intervention (acute), after 2 weeks daily supplementation (chronic), and whether 2 weeks daily supplementation altered the response to a single acute dose (acute-on-chronic). A concurrent in vitro study evaluated effects of repeated Cereboost® administration on human gut microbiota. Methods Cognitive effects of Cereboost® were assessed using a double-blind, randomized, placebo-controlled clinical trial, with 61 healthy young adults. Modulation of the gut microbiome was concurrently modelled using the Simulator of the Human Microbial Ecosystem (SHIME®), using a young adult donor. Results Consistent with previous findings, Cereboost® improved working memory and attention during the immediate postprandial period; effects that were amplified following two weeks’ treatment (acute-on-chronic) compared to acute testing alone. Chronic supplementation improved cognition on an acetylcholine-sensitive attention task and improved mental fatigue and self-assurance aspects of mood. The parallel in vitro study revealed significantly increased acetate, propionate, and butyrate levels in simulated proximal and distal colon regions, linked with observed increases in Akkermansia muciniphila and Lactobacillus. Conclusion This study confirmed the promising effects of Cereboost® on cognitive function and mood, while suggesting a possible link to alterations of the gut microbiome and modulation of acetylcholine. Further studies will be required to unravel the underlying mechanisms that are involved. Registration The study was pre-registered at ClinicalTrials.gov on 6th July 2018 (Identifier: NCT03579095).


Sign in / Sign up

Export Citation Format

Share Document